EWA vs XBI
iShares MSCI Australia ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.50% for EWA.
- • EWA pays a higher dividend yield (3.01%).
Side-by-side metrics
| Metric | EWA | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.50% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.01% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $1.45B | $10.73B |
YTD return | 8.89% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.98 | 1.10 |
P/E ratio | 20.79 | — |
Last price | $28.20 | $164.28 |
Inception | — | — |
Issuer | iShares | State Street |
EWA top holdings
| BHP.AX | BHP Group Ltd | 14.82% |
| CBA.AX | Commonwealth Bank of Australia | 13.52% |
| WBC.AX | Westpac Banking Corp | 5.91% |
| NAB.AX | National Australia Bank Ltd | 5.70% |
| ANZ.AX | ANZ Group Holdings Ltd | 5.23% |
| WES.AX | Wesfarmers Ltd | 5.04% |
| MQG.AX | Macquarie Group Ltd | 4.45% |
| RIO.AX | Rio Tinto Ltd | 3.15% |
| GMG.AX | Goodman Group | 3.05% |
| CSL.AX | CSL Ltd | 2.73% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About EWA
EWA (iShares MSCI Australia ETF) is Australian large and mid-cap equities. Managed by iShares, the fund carries $1.5B in assets under management, an expense ratio of 0.50%, a dividend yield of 3.01%. Its largest holding is BHP Group Ltd (BHP.AX), which represents 14.8% of the portfolio. Real Estate is the fund's largest sector exposure at 5.1%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.